Related Experiment Video

Updated: Mar 2, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.6K

[Cardiovascular Effects of Antidiabetic Therapies]

Katharina Laubner, Jochen Seufert

    Deutsche Medizinische Wochenschrift (1946)
    |May 18, 2017
    PubMed

    Insights

    Type 2 diabetes mellitus (T2DM) increases cardiovascular risks. Certain medications like GLP-1 RAs (Liraglutide, Semaglutide) and SGLT2 inhibitors (Empagliflozin) show cardiovascular benefits, unlike others which are neutral or less effective.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Type 2 diabetes mellitus (T2DM) is a significant risk factor for cardiovascular complications and mortality.
    • While strict glucose control is crucial long-term, non-medical therapies have limited proven cardiovascular benefits.
    • Current T2DM treatments vary in their cardiovascular impact.

    Purpose of the Study:

    • To evaluate the cardiovascular effects of various Type 2 diabetes mellitus therapies.
    • To differentiate between medications with neutral, beneficial, or uncertain cardiovascular outcomes.

    Main Methods:

    • Review of existing clinical trial data and pharmacological studies.
    • Analysis of cardiovascular outcomes associated with different classes of T2DM medications.
    • Comparison of effects for metformin, insulin, DPP4-inhibitors, GLP-1 RAs, and SGLT2 inhibitors.

    Main Results:

    • Metformin may offer positive cardiovascular effects.
    • Insulin, DPP4-inhibitors (Saxagliptin, Sitagliptin, Alogliptin), and Lixisenatide (a GLP-1 RA) appear cardiovascular neutral.
    • Liraglutide and Semaglutide (GLP-1 RAs) reduce cardiovascular outcomes, while Empagliflozin (SGLT2 inhibitor) significantly lowers cardiovascular mortality, total mortality, and heart failure hospitalizations.

    Conclusions:

    • The choice of T2DM medication can significantly influence cardiovascular risk.
    • GLP-1 RAs (Liraglutide, Semaglutide) and SGLT2 inhibitors (Empagliflozin) demonstrate clear cardiovascular benefits.
    • Further research should focus on optimizing T2DM management for cardiovascular protection.

    More Related Videos

    Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

    Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

    Published on: April 18, 2025

    697
    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

    Published on: November 29, 2024

    1.6K

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    741
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    1.2K
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    687
    Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

    Cardiovascular Drugs: Classification based on Therapeutic Indications

    Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
    4.4K
    Pathophysiology of Diabetes01:20

    Pathophysiology of Diabetes

    Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
    Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
    4.0K
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    5.2K